May 4, 2016
Recommended Topic Related To:

Viibryd

"Feb. 27, 2015 -- There may be hope for hard-to-treat depression as scientists explore novel ways to help people who have the often crippling condition.

Recently, a number of studies have suggested the benefits of Botox, ketamine, and certai"...

A A A

Viibryd




Indications
Dosage
How Supplied

INDICATIONS

VIIBRYD® is indicated for the treatment of major depressive disorder (MDD) [see Clinical Studies].

DOSAGE AND ADMINISTRATION

Dosage For Treatment Of Major Depressive Disorder

The recommended target dosage for VIIBRYD is 20 mg to 40 mg orally once daily with food [see CLINICAL PHARMACOLOGY, Clinical Studies]. To achieve the target dosage, titrate VIIBRYD as follows:

  • Start with an initial dosage of 10 mg once daily with food for 7 days,
  • Then increase to 20 mg once daily with food.
  • The dose may be increased up to 40 mg once daily with food after a minimum of 7 days between dosage increases.

If a dose is missed, it should be taken as soon as the patient remembers. If it is almost time for the next dose, the patient should skip the missed dose and take the next dose at the regular time. Two doses should not be taken at the same time.

Screen For Bipolar Disorder Prior To Starting VIIBRYD

Prior to initiating treatment with VIIBRYD or another antidepressant, screen patients for a personal or family history of bipolar disorder, mania, or hypomania [see WARNINGS AND PRECAUTIONS].

Switching To Or From A Monoamine Oxidase Inhibitor Antidepressant

At least 14 days must elapse between discontinuation of a monoamine oxidase inhibitor (MAOI) antidepressant and initiation of VIIBRYD. In addition, at least 14 days must elapse after stopping VIIBRYD before starting an MAOI antidepressant [see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS].

Dosage Adjustments With CYP3A4 Inhibitors Or Inducers

Patients Receiving Concomitant CYP3A4 Inhibitors

During concomitant use of a strong CYP3A4 inhibitor (e.g., itraconazole, clarithromycin, voriconazole), the VIIBRYD dose should not exceed 20 mg once daily. The original VIIBRYD dose level, can be resumed when the CYP3A4 inhibitor is discontinued [see DRUG INTERACTIONS].

Patients receiving Concomitant CYP3A4 Inducers

Based on clinical response, consider increasing the dosage of VIIBRYD by 2-fold, up to a maximum 80 mg once daily, over 1 to 2 weeks in patients taking strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin) for greater than 14 days. If CYP3A4 inducers are discontinued, gradually reduce the VIIBRYD dosage to its original level over 1 to 2 weeks [see DRUG INTERACTIONS].

Discontinuing Treatment With VIIBRYD

Adverse reactions may occur upon discontinuation of VIIBRYD [see WARNINGS AND PRECAUTIONS]. A gradual reduction in dosage rather than abrupt cessation is recommended whenever possible. VIIBRYD should be down tapered from the 40 mg once daily dose to 20 mg once daily for 4 days, followed by 10 mg once daily for 3 days. Patients taking VIIBRYD 20 mg once daily should be tapered to 10 mg once daily for 7 days.

HOW SUPPLIED

Dosage Forms And Strengths

VIIBRYD Tablets are available as 10 mg, 20 mg and 40 mg film-coated tablets.

10 mg pink, oval tablet, debossed with 10 on one side

20 mg orange, oval tablet, debossed with 20 on one side

40 mg blue, oval tablet, debossed with 40 on one side

Storage And Handling

VIIBRYD (vilazodone HCl) tablets are supplied in the following configurations:

Tablet Strength Tablet Color/Shape Tablet Markings Package Configuration NDC Code
10 mg pink, oval tablet debossed with 10 on one side Bottle / 30 count 0456-1110-30
20 mg orange, oval tablet debossed with 20 on one side Bottle / 30 count 0456-1120-30
40 mg blue, oval tablet debossed with 40 on one side Bottle / 30 count 0456-1140-30

VIIBRYD (vilazodone HCl) Patient Starter Kits are supplied in the following configuration:

Package Configuration Tablet Strength Tablet Color/Shape Tablet Markings NDC Code
Patient Starter Kit containing seven 10 mg tablets, seven 20 mg tablets and sixteen 40 mg tablets 10 mg pink, oval tablet debossed with 10 on one side 0456-1100-31
20 mg orange, oval tablet debossed with 20 on one side
40 mg blue, oval tablet debossed with 40 on one side
Patient Starter Kit containing seven 10 mg tablets, twenty-three 20 mg tablets 10 mg pink, oval tablet debossed with 10 on one side 0456-1101-30
20 mg orange, oval tablet debossed with 20 on one side

Store tablets at 25°C (77°F). Excursions permitted to 15°C - 30°C (59°F - 86°F) [see USP Controlled Room Temperature].

Forest Pharmaceuticals, Inc., Subsidiary of Forest Laboratories, LLC., Cincinnati, OH 45209. Licensed from Merck KGaA, Darmstadt, Germany. Revised: March 2015

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 1/9/2016

Indications
Dosage
How Supplied

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Emotional Wellness

Get tips on therapy and treatment.